You have 9 free searches left this month | to do more
Showing 1 - 25 of
1,258 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
W
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
2022-03-29
Mar 29, 2022
G
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Active, not recruiting
  • Chronic Lymphocytic Leucemia
  • Cologne, Germany
    German CLL Study Group
2021-12-13
Dec 13, 2021
G
Registry of the German CLL Study Group
Recruiting
  • CLL
  • +7 more
    • Dresden, Sachsen, Germany
      BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    2021-12-16
    Dec 16, 2021
    U
    In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • [U-13C]glucose
    • [13C5]glutamine
    • (no location specified)
    2022-03-18
    Mar 18, 2022
    P
    Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • (no location specified)
    2022-04-02
    Apr 2, 2022
    G
    Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)
    Active, not recruiting
    • Chronic Lymphocytic Leucemia
    • Cologne, Germany
      German CLL Study Group
    2021-08-23
    Aug 23, 2021
    A
    Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL
    Not yet recruiting
    • CLL Progression
    • Emerald
    • (no location specified)
    2021-03-22
    Mar 22, 2021
    M
    Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
    Not yet recruiting
    • CLL
    • (no location specified)
    2022-02-08
    Feb 8, 2022
    A
    CLL Therapy Approaches in Russia
    Recruiting
    • Chronic Lymphocytic Leukemia
      • Irkutsk, Russian Federation
      • +5 more
      2022-03-30
      Mar 30, 2022
      W
      Early Intervention With Acalabrutinib in Patients With High Risk CLL
      Withdrawn
      • Chronic Lymphocytic Leukemia
      • CLL/SLL
      • New York, New York
        Weill Cornell Medicine
      2022-03-25
      Mar 25, 2022
      U
      Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
      Recruiting
      • CLL
      • B-cell Non Hodgkin Lymphoma
      • New Haven, Connecticut
      • +2 more
      2022-01-07
      Jan 7, 2022
      U
      Personalized Multi-peptide Vaccination in CLL Patients
      Recruiting
      • Chronic Lymphocytic Leukemia
      • Multipeptide Vaccine+ XS15
      • Tuebingen, BW, Germany
      • +1 more
      2021-09-07
      Sep 7, 2021
      U
      Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
      Recruiting
      • Chronic Lymphocytic Leukemia
      • San Diego, California
        UCSD Koman Family Outpatient Pavilion
      2021-11-24
      Nov 24, 2021
      R
      Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
      Recruiting
      • CLL
      • Copenhagen, Denmark
      • +5 more
      2021-09-17
      Sep 17, 2021
      N
      HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) - 2020
      Completed
      Has Results
      • Hepatitis
      • Safety and Tolerability
      • HEPLISAV-B
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-01-13
      Jan 13, 2022
      P
      Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • Ibrutinib and obinutuzumab
      • (no location specified)
      2021-08-23
      Aug 23, 2021
      N
      Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
      Active, not recruiting
      • Multiple Myeloma
      • +4 more
      • Total Body Irradiation
      • +5 more
      • Los Angeles, California
        Cedars Sinai Medical Center
      2021-12-01
      Dec 1, 2021
      D
      Safe Accelerated Venetoclax Escalation in CLL
      Recruiting
      • Chronic Lymphocytic Leukemia
      • Small Lymphocytic Lymphoma
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      2021-09-08
      Sep 8, 2021
      G
      A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
      Active, not recruiting
      • Chronic Lymphocytic Leukemia
      • Washington, District of Columbia
      • +1 more
      2022-03-14
      Mar 14, 2022
      D
      Copanlisib Plus Ibrutinib in R/R CLL
      Recruiting
      • Chronic Lymphocytic Leukemia (CLL)
      • +2 more
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      2021-09-08
      Sep 8, 2021
      G
      Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL - 2013
      Completed
      • NHL
      • +17 more
      • veltuzumab
      • Savannah, Georgia
      • +4 more
      2021-08-12
      Aug 12, 2021
      U
      A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
      Recruiting
      • Relapsed Chronic Lymphocytic Leukemia
      • Ann Arbor, Michigan
        University of Michigan Comprehensive Cancer Center
      2021-12-16
      Dec 16, 2021
      W
      Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL - 2020
      Completed
      Has Results
      • Chronic Lymphocytic Leukemia
      • New York, New York
        Weill Cornell Medical College
      2021-12-23
      Dec 23, 2021
      U
      iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
      Recruiting
      • Leukemia, Chronic Lymphatic
      • Stuttgart, Baden-Wuerttemberg, Germany
      • +4 more
      2021-09-30
      Sep 30, 2021
      G
      Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation - 2019
      Terminated
      • Chronic Lymphocytic Leukemia
      • Richter's Transformation
      • Obinutuzumab
      • Bonn, Germany
      • +6 more
      2021-12-16
      Dec 16, 2021